Trial Profile
Rh-endostatin [Endostar] Injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: Randomized, double-blind, placebo-controlled, multicentre study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2012
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Sponsors Shandong Simcere Medgenn Bio-Pharmaceutical
- 05 Jun 2012 Biomarker analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 28 Apr 2011 Primary endpoint 'Progression-free-survival' has not been met, based on results published in the Journal of Thoracic Oncology.
- 28 Apr 2011 Results published in the Journal of Thoracic Oncology.